Last reviewed · How we verify
intravenous injection of test solution
The intravenous injection of test solution, developed by the University Children's Hospital, Zurich, is currently marketed but lacks detailed information on its mechanism and primary indication. A key strength is the protection provided by the key composition patent, which expires in 2028. The primary risk is the lack of clear revenue data and key trial results, which may impact investor confidence and market positioning.
At a glance
| Generic name | intravenous injection of test solution |
|---|---|
| Sponsor | University Children's Hospital, Zurich |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- DaTSCAN Imaging in Aging and Neurodegenerative Disease (PHASE4)
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (PHASE3)
- First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers. (PHASE1)
- The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (NA)
- A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis (PHASE1, PHASE2)
- Intralipid® 20% for Reversal of Local Anesthetics (PHASE4)
- A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) (PHASE2)
- A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: